TMCnet News
NeuroMetrix Expands Intellectual Property for Wearable Pain Relief TechnologyNeuroMetrix, Inc. (Nasdaq: NURO) reported today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering unique aspects of the Company's wearable pain relief technology. The patent addresses an important element in the Company proprietary OptiTherapy™ technology that automatically controls nerve stimulation to optimize pain relief. In particular, the patent covers the automated calibration procedure that determines the appropriate stimulation level for each device user. The Company expects the patent to issue in mid-2015 and to extend patent protection into 2032. The technology is incorporated in the currently marketed prescription SENSUS® pain management device and in Quel™ which will be unveiled at the International Consumer Electronics Show (CES (News - Alert)) in Las Vegas in January 2015. Quell™ utilizes NeuroMetrix's proprietary non-invasive neurostimulation technology to provide relief from chronic pain, particularly neuropathic pain such as due to diabetes and lower back problems. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. Users of the device will also have the option of using their smartphone to automatically track and personalize their pain therapy. The Company expects Quell™ to be available for purchase by consumers in the second quarter of 2015. About NeuroMetrix NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit http://www.NeuroMetrix.com.
|
